Development of a bedside scoring system for predicting a first recurrence of Clostridium difficile-associated diarrhea

American Journal of Health-System Pharmacy

Volumn 74, Issue 7, 2017, Pages 474-482

  Viswesh, Velliyur ^a   Hincapie, Ana L ^b   Yu, Marie ^c   Khatchatourian, Linda ^d   Nowak, Michael A ^e  

^a ROSEMAN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c SHARP GROSSMONT HOSPITAL   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e ALLERGAN PLC   (United States)

Author keywords

Clostridium difficile; Diarrhea; Recurrence; Scoring system

Indexed keywords

ANTIDEPRESSANT AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METRONIDAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL DISTENTION; ADULT; AGED; ARTICLE; BODY TEMPERATURE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; FEMALE; HOSPITAL INFECTION; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; PHYSICAL EXAMINATION; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RETROSPECTIVE STUDY; SCORING SYSTEM; STOMACH FUNCTION DISORDER; CLOSTRIDIUM INFECTION; DIARRHEA; ISOLATION AND PURIFICATION; MALE; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; VALIDATION STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 85016213683     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp160186     Document Type: Article

References (34)

1. Magill SS, Edwards JR, Bamberg W et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014; 370:1198-208.
2. Evans CT, Safdar N. Current trends in the epidemiology and outcomes of Clostridium difficile infection. Clin Infect Dis. 2015; 60(suppl 2):S66-71.
3. Antibiotic resistance threats in the United States, 2013. www.cdc.gov/drugresistance/threat-report-2013/index.html (accessed 2016 Feb 12).
4. Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013; 108:478-99.
5. Deshpande A, Pasupuleti V, Thota P et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015; 36:452-60.
6. Maroo S, Lamont JT. Recurrent Clostridium difficile. Gastroenterology. 2006; 130:1311-6.
7. Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012; 12:281-9.
8. Cornely OA, Miller MA, Louie TJ et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012; 55(suppl 2):S154-61.
9. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011; 364:422-31.
10. Aroniadis OC, Brandt LJ, Greenberg A et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol. 2016; 50:398-402.
11. Eyre DW, Walker AS, Wyllie D et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis. 2012; 55(suppl 2):S77-87.
12. Miller MA, Louie T, Mullane K et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis. 2013; 13:148.
13. Jacobson SM, Slain D. Evaluation of a bedside scoring system for predicting clinical cure and recurrence of Clostridium difficile infections. Am J Health-Syst Pharm. 2015; 72:1871-5.
14. Brown KA, Khanafer N, Daneman N et al. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013; 57:2326-32.
15. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2013; 69:881-91.
16. Baggs J, Yousey-Hindes K, Ashley ED et al. Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials. Vaccine. 2015; 33:6241-9.
17. Rogers MA, Greene MT, Young VB et al. Depression, antidepressant medications, and risk of Clostridium difficile infection. BMC Med. 2013; 11:121.
18. Park SW, Choi AR, Lee HJ et al. The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients. Aliment Pharmacol Ther. 2013; 38:619-27.
19. Saliba W, Barnett-Griness O, Elias M et al. Statins use and risk of mortality in patient with Clostridium difficile infection. Clin Microbiol Infect. 2014; 20:1061-6.
20. Steyerberg EW, Harrell FE Jr, Borsboom GJ et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001; 54:774-81.
21. Smith GC, Seaman SR, Wood AM et al. Correcting for optimistic prediction in small data sets. Am J Epidemiol. 2014; 180:318-24.
22. Freedberg DE, Salmasian H, Friedman C et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol. 2013; 108:1794-801.
23. McDonald EG, Milligan J, Frenette C et al. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med. 2015; 175:784-91.
24. Weiss K, Louie T, Miller MA et al. Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea. BMJ Open Gastroenterol. 2015; 2:e000028.
25. Allen SJ, Wareham K, Wang D et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013; 382:1249-57.
26. Allen SJ, Wareham K, Wang D et al. A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE). Health Technol Assess. 2013; 17(57):1-140.
27. Wenisch JM, Schmid D, Kuo HW et al. Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2012; 56:1974-8.
28. Thiercelin JF, Diquet B, Levesque C et al. Metronidazole kinetics and bioavailability in patients undergoing gastrointestinal surgery. Clin Pharmacol Ther. 1984; 35:510-9.
29. Abou Chakra CN, Pepin J, Valiquette L. Prediction tools for unfavourable outcomes in Clostridium difficile infection: a systematic review. PLoS ONE. 2012; 7(1):e30258.
30. Hu MY, Katchar K, Kyne L et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology. 2009; 136:1206-14.
31. Nathwani D, Cornely OA, van Engen AK et al. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother. 2014; 69:2901-12.
32. Gallagher JC, Reilly JP, Navalkele B et al. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection. Antimicrob Agents Chemother. 2015; 59:7007-10.
33. Zhanel GG, Walkty AJ, Karlowsky JA. Fidaxomicin: a novel agent for the treatment of Clostridium difficile infection. Can J Infect Dis Med Microbiol. 2015; 26:305-12.
34. Sclar DA, Robison LM, Oganov AM et al. Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price. Clin Drug Investig. 2012; 32(8):e17-24.